Market News

Citigroup Upped Holding in Corcept Therapeutics (Put) (CORT); Kylin Management Has Lowered Its Netease (NTES) Stake by $26.08 Million

Corcept Therapeutics Incorporated (NASDAQ:CORT) Logo

Citigroup Inc increased its stake in Corcept Therapeutics Inc (Put) (CORT) by 8360% based on its latest 2017Q4 regulatory filing with the SEC. Citigroup Inc bought 41,800 shares as the company’s stock declined 9.45% with the market. The institutional investor held 42,300 shares of the major pharmaceuticals company at the end of 2017Q4, valued at $764,000, up from 500 at the end of the previous reported quarter. Citigroup Inc who had been investing in Corcept Therapeutics Inc (Put) for a number of months, seems to be bullish on the $2.06 billion market cap company. The stock increased 1.48% or $0.26 during the last trading session, reaching $17.87. About 775,977 shares traded. Corcept Therapeutics Incorporated (NASDAQ:CORT) has risen 52.11% since May 16, 2017 and is uptrending. It has outperformed by 40.56% the S&P500.

Ted Kang decreased its stake in Netease Inc (NTES) by 52.98% based on its latest 2017Q4 regulatory filing with the SEC. Kylin Management Llc sold 75,600 shares as the company’s stock declined 23.21% with the market. The hedge fund run by Ted Kang held 67,100 shares of the miscellaneous company at the end of 2017Q4, valued at $23.15 million, down from 142,700 at the end of the previous reported quarter. Kylin Management Llc who had been investing in Netease Inc for a number of months, seems to be less bullish one the $35.06B market cap company. The stock increased 0.22% or $0.5902 during the last trading session, reaching $266.9402. About 1.22 million shares traded or 18.15% up from the average. NetEase, Inc. (NASDAQ:NTES) has declined 2.94% since May 16, 2017 and is downtrending. It has underperformed by 14.49% the S&P500.

Among 20 analysts covering NetEase (NASDAQ:NTES), 13 have Buy rating, 4 Sell and 3 Hold. Therefore 65% are positive. NetEase had 46 analyst reports since August 12, 2015 according to SRatingsIntel. The rating was maintained by Bernstein with “Sell” on Tuesday, February 27. The rating was maintained by Jefferies with “Hold” on Tuesday, April 10. Jefferies maintained the shares of NTES in report on Tuesday, January 23 with “Hold” rating. On Monday, January 9 the stock rating was upgraded by Standpoint Research to “Buy”. As per Thursday, February 25, the company rating was maintained by JP Morgan. Jefferies upgraded the stock to “Buy” rating in Monday, November 28 report. Nomura upgraded the shares of NTES in report on Thursday, May 12 to “Buy” rating. The stock of NetEase, Inc. (NASDAQ:NTES) earned “Buy” rating by CLSA on Wednesday, April 25. The company was downgraded on Friday, October 16 by Standpoint Research. The stock of NetEase, Inc. (NASDAQ:NTES) earned “Outperform” rating by Macquarie Research on Wednesday, September 28.

Kylin Management Llc, which manages about $2.25 billion and $811.15M US Long portfolio, upped its stake in Cognex Corp (NASDAQ:CGNX) by 1.78 million shares to 2.97 million shares, valued at $181.46 million in 2017Q4, according to the filing.

More notable recent NetEase, Inc. (NASDAQ:NTES) news were published by: Seekingalpha.com which released: “NetEase: Great Products In An Attractive Market” on April 19, 2018, also Benzinga.com with their article: “Earnings Scheduled For May 16, 2018” published on May 16, 2018, Streetinsider.com published: “Viking Global’s 13F Shows New Stakes in Alibaba (BABA), BioMarin (BMRN) and Western Digital (WDC), Increase in …” on May 15, 2018. More interesting news about NetEase, Inc. (NASDAQ:NTES) were released by: Nasdaq.com and their article: “NetEase Chases Alibaba and JD.com With a “Knockoff Marketplace”” published on April 28, 2018 as well as Fool.com‘s news article titled: “Can NetEase Stock Bounce Back on Wednesday?” with publication date: May 15, 2018.

More recent Corcept Therapeutics Incorporated (NASDAQ:CORT) news were published by: Nasdaq.com which released: “Corcept Therapeutics Announces Presentations at the American Association of Clinical Endocrinologists 27th Annual …” on May 16, 2018. Also Seekingalpha.com published the news titled: “Corcept Therapeutics’ (CORT) CEO Joseph Belanoff on Q1 2018 Results – Earnings Call Transcript” on May 09, 2018. Nasdaq.com‘s news article titled: “Corcept Therapeutics Announces First Quarter 2018 Financial results and Provides Corporate Update” with publication date: May 08, 2018 was also an interesting one.

Among 7 analysts covering Corcept Therapeutics (NASDAQ:CORT), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Corcept Therapeutics had 11 analyst reports since February 2, 2017 according to SRatingsIntel. The stock of Corcept Therapeutics Incorporated (NASDAQ:CORT) earned “Buy” rating by Stifel Nicolaus on Friday, November 3. The firm has “Buy” rating given on Wednesday, October 11 by Piper Jaffray. The rating was initiated by Seaport Global on Friday, April 13 with “Buy”. As per Thursday, February 2, the company rating was initiated by Ladenburg Thalmann. FBR Capital maintained the stock with “Buy” rating in Tuesday, March 20 report. Piper Jaffray maintained the stock with “Buy” rating in Thursday, August 24 report. On Friday, September 8 the stock rating was maintained by Piper Jaffray with “Buy”. The stock of Corcept Therapeutics Incorporated (NASDAQ:CORT) earned “Buy” rating by FBR Capital on Thursday, March 8.

Citigroup Inc, which manages about $124.75 billion US Long portfolio, decreased its stake in Atlantica Yield Plc (Put) by 77,400 shares to 600 shares, valued at $13,000 in 2017Q4, according to the filing. It also reduced its holding in Disney Walt Co (Call) (NYSE:DIS) by 34,700 shares in the quarter, leaving it with 1.13M shares, and cut its stake in Molson Coors Brewing Co (Put) (NYSE:TAP).

Corcept Therapeutics Incorporated (NASDAQ:CORT) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *